Teva Pharmaceutical Industries (TEVJF) Net Cash Flow (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Net Cash Flow across 10 years of filings, most recently posting $202.0 million for Q1 2026.

• Quarterly Net Cash Flow rose 112.26% year-over-year to $202.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (up 264.3% YoY) and the FY2025 annual result came in at $235.0 million, down 5.24% from the prior year.
• Net Cash Flow declined to $202.0 million in Q1 2026, from $1.4 billion in the prior quarter.
• Over five years, Net Cash Flow peaked at $1.4 billion in Q4 2025 and troughed at -$1.6 billion in Q1 2025.
• A 5-year average of $109.8 million and a median of $114.0 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow surged 1686.11% — and 2025, when it plunged 1158.02%.
• Tracing TEVJF's Net Cash Flow over 5 years: stood at $430.0 million in 2022, then surged by 111.4% to $909.0 million in 2023, then sank by 88.67% to $103.0 million in 2024, then soared by 1223.3% to $1.4 billion in 2025, then tumbled by 85.18% to $202.0 million in 2026.
• Business Quant data shows TEVJF's Net Cash Flow at $202.0 million in Q1 2026, $1.4 billion in Q4 2025, and $51.0 million in Q3 2025.